المؤلفون: Culine S; Department of Medical Oncology, Saint-Louis Hospital, AP-HP, Faculté de Paris, France. Electronic address: stephane.culine@aphp.fr., Harter V; North-West Canceropole Data Center, Baclesse Cancer Center, Caen, France., Gravis G; Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France., Fléchon A; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France., Chevreau C; Department of Medical Oncology, ICR-IUCT Oncopole, Toulouse, France., Mahammedi H; Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France., Laguerre B; Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France., Guillot A; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, St Priest en Jarez, France., Joly F; Department of Medical Oncology, Baclesse Cancer Center, Caen, France., Abadie-Lacourtoisie S; Department of Medical Oncology, Institut de cancérologie de l'Ouest, Angers, France., Geoffrois L; Department of Medical Oncology, Lorraine-Alexis Vautrin Cancer Institute, Nancy, France., Fiore FD; Digestive and uro-oncology Unit, Charles Nicolle University Hospital, Rouen, France., Roubaud G; Department of Medical Oncology, Bergonié Institute, Bordeaux, France., Barthélémy P; Department of Medical Oncology, University Hospital, Strasbourg, France., Voog E; Victor Hugo Clinic, Le Mans, France., Emambux S; Department of Medical Oncology, University Hospital, Poitiers, France., Serrate C; Department of Medical Oncology, Diaconesses Croix Saint-Simon Hospital, Paris, France., Saldana C; Department of Medical Oncology, Henri Mondor University Hospital, AP-HP, Créteil, France., Nguyen-Tan-Hon T; Department of Medical Oncology, University Hospital, Besançon, France., Loriot Y; Department of Cancer Medicine, Gustave Roussy, Inserm U981, Villejuif, France., Eymard JC; Department of Medical Oncology, Jean Godinot Institute, Reims, France., Huillard O; Department of Medical Oncology, Cochin Port-Royal University Hospital, AP-HP Centre, Paris, France., Rolland F; Department of Medical Oncology, West County Cancer Institute, Nantes, France., Houédé N; Gard Cancer Institute, University Hospital, Nîmes, Inserm U1194 Montpellier Cancer Institute, Montpellier University, Nimes, France., Spano JP; Department of Medical Oncology, Pitié Salpétrière University Hospital, AP-HP-SU, IUC, Paris, France., Demery ME; Department of Oncology, Cap d'Or Clinic, La Seyne sur Mer, France., Vieillot S; Department of Oncology, Saint-Pierre Clinic, Perpignan, France., L'Haridon T; Department of Medical Oncology, Vendée Regional Hospital, La Roche-sur-Yon, France., Hilgers W; Uro-Oncology Unit, Sainte Catherine Institute, Avignon, France., Allory Y; Department of Pathology, Curie Institute, Saint-Cloud, France., Pfister C; Department of Urology and Clinical Investigation Center, Inserm 1404, Charles Nicolle University Hospital, Rouen, France.

مؤلفون مشاركون: VESPER Trial Investigators

المصدر: Clinical genitourinary cancer [Clin Genitourin Cancer] 2021 Dec; Vol. 19 (6), pp. 554-562. Date of Electronic Publication: 2021 Sep 08.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/therapeutic use , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/surgery, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Cystectomy ; Doxorubicin/therapeutic use ; Humans ; Kidney/physiology ; Methotrexate/therapeutic use ; Muscles ; Neoadjuvant Therapy ; Retrospective Studies ; Vinblastine/therapeutic use

المؤلفون: Laurent M; Internal Medicine and Geriatric Department, Henri-Mondor Hospital, APHP, Créteil, France; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France. Electronic address: marie.laurent@aphp.fr., Brureau L; Medicine Department, Gustave Roussy Cancer Center, Villejuif, France., Demery ME; Department of Oncology, Clinique du Cap d'Or, La Seyne sur Mer, France., Fléchon A; Department of Medical Oncology, Leon Bérard Cancer Center, Lyon, France., Thuaut AL; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France; Public Health Department, Henri-Mondor Hospital, APHP, Créteil, France; Clinical Research Unit (URC Mondor), Henri-Mondor Hospital, APHP, Créteil, France., Carvahlo-Verlinde M; Department of Pharmacy, Henri-Mondor Hospital, APHP, Créteil, France., Bastuji-Garin S; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France; Public Health Department, Henri-Mondor Hospital, APHP, Créteil, France; Clinical Research Unit (URC Mondor), Henri-Mondor Hospital, APHP, Créteil, France., Paillaud E; Internal Medicine and Geriatric Department, Henri-Mondor Hospital, APHP, Créteil, France; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France., Canoui-Poitrine F; CEpiA (Clinical Epidemiology and Aging) Unit, UPEC A-TVB DHU, IMRB,EA 7376 CEpiA University Paris Est (UPE), Créteil, France; Public Health Department, Henri-Mondor Hospital, APHP, Créteil, France; Clinical Research Unit (URC Mondor), Henri-Mondor Hospital, APHP, Créteil, France., Culine S; Department of Medical Oncology, Saint-Louis Hospital, AP-HP, Paris, France; University Paris Diderot, Paris, France.

المصدر: Urologic oncology [Urol Oncol] 2017 Jan; Vol. 35 (1), pp. 34.e9-34.e16. Date of Electronic Publication: 2016 Oct 06.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Withholding Treatment*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Urinary Bladder Neoplasms/*drug therapy , Urinary Bladder Neoplasms/*mortality, Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Carboplatin/administration & dosage ; Cisplatin/administration & dosage ; Creatinine/blood ; Creatinine/urine ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Female ; Health Status ; Humans ; Male ; Neoplasm Metastasis ; Prospective Studies ; Serum Albumin/metabolism ; Survival Rate ; Time Factors ; Tumor Burden ; Urinary Bladder Neoplasms/pathology ; Gemcitabine

المؤلفون: Demery ME; Department of Medical Oncology, University Hospital, Nîmes, France., Thézenas S, Pouessel D, Culine S

المصدر: Anti-cancer drugs [Anticancer Drugs] 2012 Feb; Vol. 23 (2), pp. 143-8.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Transitional Cell/*drug therapy , Kidney/*physiopathology , Urologic Neoplasms/*drug therapy , Urothelium/*pathology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carboplatin/therapeutic use ; Carcinoma, Transitional Cell/mortality ; Carcinoma, Transitional Cell/pathology ; Carcinoma, Transitional Cell/physiopathology ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Disease-Free Survival ; Humans ; Kidney Function Tests ; Neoplasm Invasiveness ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Paclitaxel/therapeutic use ; Randomized Controlled Trials as Topic ; Urologic Neoplasms/mortality ; Urologic Neoplasms/pathology ; Urologic Neoplasms/physiopathology ; Gemcitabine